Psychiatrie und Psychotherapie up2date, Table of Contents Psychiatrie und Psychotherapie up2date 2012; 6(04): 201-212DOI: 10.1055/s-0032-1305049 Organische psychische Störungen © Georg Thieme Verlag KG Stuttgart · New York Biomarker und Demenz Rüdiger Zimmermann , Johannes Kornhuber , Piotr Lewczuk Recommend Article Abstract Buy Article All articles of this category Full Text References Literatur 1 Clarfield AM. The decreasing prevalence of reversible dementias: an updated meta-analysis. Arch Intern Med 2003; 163: 2219-2229 2 Lewczuk P, Esselmann H, Otto M et al. Neurochemical diagnosis of Alzheimer’s dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging 2004; 25: 273-281 3 Riemenschneider M, Schmolke M, Lautenschlager N et al. Cerebrospinal beta-amyloid (1-42) in early Alzheimer’s disease: association with apolipoprotein E genotype and cognitive decline. Neurosci Lett 2000; 284: 85-88 4 Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx 2004; 1: 213-225 5 Andreasen N, Blennow K. CSF biomarkers for mild cognitive impairment and early Alzheimer’s disease. Clin Neurol Neurosurg 2005; 107: 165-173 6 Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2003; 2: 605-613 7 Lewczuk P, Esselmann H, Bibl M et al. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer’s disease: original data and review of the literature. J Mol Neurosci 2004; 23: 115-122 8 Hampel H, Buerger K, Zinkowski R et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 2004; 61: 95-102 9 Engelborghs S, De Vreese K, Van De Casteele T et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 2008; 29: 1143-1159 10 Tapiola T, Alafuzoff I, Herukka SK et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009; 66: 382-389 11 Zetterberg H, Wahlund LO, Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer’s disease. Neurosci Lett 2003; 352: 67-69 12 WHO. Dilling H, Mombour W et al. Internationale Klassifikation psychischer Störungen: ICD-10 Kapitel V (F). Klinisch-diagnostische Leitlinien. Bd. 6. Bern: Huber; 2008 13 Zimmermann R, Lelental N, Ganslandt O et al. Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics. J Alzheimers Dis 2011; 25: 739-745 14 Vanderstichele H, Bibl M, Engelborghs S et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: A consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimers Dement 2011; [in press] 15 Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-746 16 Herholz K, Ebmeier K. Clinical amyloid imaging in Alzheimer’s disease. Lancet Neurol 2011; 10: 667-670 17 Dougall NJ, Bruggink S, Ebmeier KP. Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. American J Geriat Psychiatry 2004; 12: 554-570 18 Dubois B, Feldman HH, Jacova C et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 2010; 9: 1118-1127 19 Lewczuk P, Kamrowski-Kruck H, Peters O et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer’s disease: a multicenter study. Mol Psychiatry 2010; 15: 138-145 20 Funke SA, Birkmann E, Henke F et al. Single particle detection of Abeta aggregates associated with Alzheimer’s disease. Biochem Biophys Res Commun 2007; 364: 902-907 21 Mattsson N, Blennow K, Zetterberg H. CSF biomarkers: pinpointing Alzheimer pathogenesis. Ann N Y Acad Sci 2009; 1180: 28-35 22 Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 2001; 310: 173-186 23 Felgenhauer K, Beuche W. Labordiagnostik neurologischer Erkrankungen: Liquoranalytik und -zytologie, Diagnose- und Prozessmarker. Stuttgart: Thieme; 1999 24 Preston SD, Steart PV, Wilkinson A et al. Capillary and arterial cerebral amyloid angiopathy in Alzheimer’s disease: defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropathol Appl Neurobiol 2003; 29: 106-117 25 Van Oijen M, Hofman A, Soares HD et al. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 2006; 5: 655-660 26 Mayeux R, Honig LS, Tang MX et al. Plasma A[beta]40 and A[beta]42 and Alzheimer’s disease: relation to age, mortality, and risk. Neurology 2003; 61: 1185-1190 27 Graff-Radford NR, Crook JE, Lucas J et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007; 64: 354-362 28 Lewczuk P, Kornhuber J, Vanmechelen E et al. Amyloid beta peptides in plasma in early diagnosis of Alzheimer’s disease: A multicenter study with multiplexing. Exp Neurol 2010; 223: 366-370 29 Lewczuk P, Beck G, Ganslandt O et al. International quality control survey of neurochemical dementia diagnostics. Neurosci Lett 2006; 409: 1-4 30 Verwey NA, Van Der Flier WM, Blennow K et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer’s disease. Ann Clin Biochem 2009; 46: 235-240
